IXICO plc (PHYOF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.7 Million USD | 7.39% |
| 2022 | 5.19 Million USD | -20.19% |
| 2021 | 6.51 Million USD | -11.17% |
| 2020 | 7.33 Million USD | 18.37% |
| 2019 | 6.19 Million USD | 8.73% |
| 2018 | 5.69 Million GBP | 3.73% |
| 2017 | 5.49 Million GBP | -1.64% |
| 2016 | 5.58 Million GBP | 79.56% |
| 2015 | 3.11 Million GBP | -44.78% |
| 2014 | 5.63 Million GBP | 8.51% |
| 2013 | 5.19 Million GBP | -44.28% |
| 2012 | 9.31 Million GBP | 8.14% |
| 2011 | 8.61 Million GBP | 72.9% |
| 2010 | 4.98 Million GBP | 11.88% |
| 2009 | 4.45 Million GBP | -14.02% |
| 2008 | 5.17 Million GBP | 0.0% |
| 2007 | - GBP | -100.0% |
| 2006 | 8.15 Million GBP | -25.3% |
| 2005 | 10.91 Million GBP | 35.39% |
| 2004 | 8.06 Million GBP | -3.77% |
| 2003 | 8.38 Million GBP | 19.94% |
| 2002 | 6.98 Million GBP | 39.32% |
| 2001 | 5.01 Million GBP | 10.56% |
| 2000 | 4.53 Million GBP | -19.96% |
| 1999 | 5.66 Million GBP | 22.74% |
| 1998 | 4.61 Million GBP | 28.29% |
| 1997 | 3.59 Million GBP | 122.3% |
| 1996 | 1.61 Million GBP | 113.03% |
| 1995 | 760 Thousand GBP | -64.94% |
| 1994 | 2.16 Million GBP | 114.65% |
| 1993 | 1.01 Million GBP | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.45 Million USD | 0.0% |
| 2023 FY | 5.58 Million USD | 7.39% |
| 2023 Q2 | 2.91 Million USD | 0.0% |
| 2023 Q4 | 2.8 Million USD | 0.0% |
| 2022 Q4 | 2.49 Million USD | 0.0% |
| 2022 Q2 | 3.01 Million USD | 0.0% |
| 2022 FY | 5.19 Million USD | -20.19% |
| 2021 Q2 | 3.66 Million USD | 0.0% |
| 2021 Q4 | 3.21 Million USD | 0.0% |
| 2021 FY | 6.51 Million USD | -11.17% |
| 2020 Q4 | 3.78 Million USD | 0.0% |
| 2020 FY | 7.33 Million USD | 18.37% |
| 2020 Q2 | 3.38 Million USD | 0.0% |
| 2019 FY | 6.19 Million USD | 8.73% |
| 2019 Q4 | 3.22 Million USD | 0.0% |
| 2018 FY | 5.69 Million GBP | 3.73% |
| 2017 FY | 5.49 Million GBP | -1.64% |
| 2016 FY | 5.58 Million GBP | 79.56% |
| 2015 FY | 3.11 Million GBP | -44.78% |
| 2014 FY | 5.63 Million GBP | 8.51% |
| 2013 FY | 5.19 Million GBP | -44.28% |
| 2012 FY | 9.31 Million GBP | 8.14% |
| 2011 FY | 8.61 Million GBP | 72.9% |
| 2010 FY | 4.98 Million GBP | 11.88% |
| 2009 FY | 4.45 Million GBP | -14.02% |
| 2008 FY | 5.17 Million GBP | 0.0% |
| 2007 FY | - GBP | -100.0% |
| 2006 FY | 8.15 Million GBP | -25.3% |
| 2005 FY | 10.91 Million GBP | 35.39% |
| 2004 FY | 8.06 Million GBP | -3.77% |
| 2003 FY | 8.38 Million GBP | 19.94% |
| 2002 FY | 6.98 Million GBP | 39.32% |
| 2001 FY | 5.01 Million GBP | 10.56% |
| 2000 FY | 4.53 Million GBP | -19.96% |
| 1999 FY | 5.66 Million GBP | 22.74% |
| 1998 FY | 4.61 Million GBP | 28.29% |
| 1997 FY | 3.59 Million GBP | 122.3% |
| 1996 FY | 1.61 Million GBP | 113.03% |
| 1995 FY | 760 Thousand GBP | -64.94% |
| 1994 FY | 2.16 Million GBP | 114.65% |
| 1993 FY | 1.01 Million GBP | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -252.47% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 6.645% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 84.073% |
| Nascent Biotech, Inc. | 2.22 Million USD | -111.088% |
| Rebus Holdings, Inc. | 664 Thousand USD | -608.886% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 87.366% |
| Qrons Inc. | 643.67 Thousand USD | -631.267% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1108.268% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 91.805% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1032.909% |
| Skye Bioscience, Inc. | 13.54 Million USD | 65.256% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 94.576% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 4.289% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1698.446% |
| SQZ Biotechnologies Company | 85.61 Million USD | 94.502% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -61.407% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -213.403% |
| Mesoblast Limited | 5.9 Million USD | 20.247% |
| Marizyme, Inc. | 19.23 Million USD | 75.535% |
| Genus plc | 147.7 Million USD | 96.813% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 46.385% |
| Pharming Group N.V. | 225.49 Million USD | 97.913% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -129.755% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -250.864% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 43.554% |
| ContraFect Corporation | 56.88 Million USD | 91.726% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -6.767% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -218.309% |
| IMV Inc. | 37.7 Million USD | 87.518% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -68.688% |
| MultiCell Technologies, Inc. | 567.42 USD | -829444.253% |
| ONE Bio Corp. | 6.44 Million USD | 26.954% |
| Accustem Sciences Inc. | 3.74 Million USD | -25.64% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 94.523% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -784.838% |
| Q BioMed Inc. | 3.43 Million USD | -36.966% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 80.955% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -79.142% |
| Biomind Labs Inc. | 994.18 Thousand USD | -373.455% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 95.261% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -167.492% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 29.935% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -152.471% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 18928.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 70.6% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -156.499% |
| GB Sciences, Inc. | 1.42 Million USD | -231.36% |
| Alpha Cognition Inc. | 9.7 Million USD | 51.502% |
| HST Global, Inc. | 140.9 Thousand USD | -3240.501% |
| CSL Limited | 3.44 Billion USD | 99.864% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -318.433% |
| Halberd Corporation | 74.84 Thousand USD | -6189.249% |
| Enzolytics Inc. | 2.17 Million USD | -115.966% |
| Agentix Corp. | 1.37 Million USD | -243.137% |
| Resverlogix Corp. | 12.71 Million USD | 62.972% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -28.934% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.693% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -350.862% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -95.723% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -198.033% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -38.239% |
| AVAX Technologies, Inc. | 7.31 Million USD | 35.611% |
| Zenith Capital Corp. | 8.94 Million USD | 47.367% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.43% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -26919.115% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -91.706% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2644.462% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -145.041% |
| Kadimastem Ltd | 2.41 Million USD | -95.302% |
| Helix BioMedix, Inc. | 1.97 Million USD | -138.688% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 56.685% |
| BioStem Technologies, Inc. | 22.97 Million USD | 79.512% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -2493.603% |
| LadRx Corporation | 3.81 Million USD | -23.485% |
| Cell Source, Inc. | 4.32 Million USD | -8.824% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -409.686% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -409.686% |
| NovAccess Global Inc. | 2.46 Million USD | -90.817% |
| Affymax, Inc. | 39.38 Million USD | 88.049% |
| Itoco Inc. | 919.14 Thousand USD | -412.107% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -11.056% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -320.643% |
| Mobile Lads Corp. | 554.54 Thousand USD | -748.802% |
| CytoDyn Inc. | 18.05 Million USD | 73.934% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -18601.577% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -2038.787% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -231.527% |
| SYBLEU INC | 160.87 Thousand USD | -2825.856% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -159.15% |
| International Stem Cell Corporation | 5.27 Million USD | 10.7% |
| Bioxytran, Inc. | 3.82 Million USD | -23.215% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -8841.53% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -23038.18% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 87.021% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -190.915% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -539.681% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -51.302% |
| Neutra Corp. | 243.82 Thousand USD | -1830.515% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 73.037% |
| PureTech Health plc | 144.59 Million USD | 96.745% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 77.028% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 46.493% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 96.002% |
| CSL Limited | 3.89 Billion USD | 99.879% |
| Cellectis S.A. | 97.32 Million USD | 95.163% |